Algert Global LLC Grows Position in DexCom, Inc. $DXCM

Algert Global LLC grew its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 750.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 51,579 shares of the medical device company's stock after purchasing an additional 45,513 shares during the quarter. Algert Global LLC's holdings in DexCom were worth $3,474,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of DXCM. Norges Bank purchased a new position in shares of DexCom in the 4th quarter valued at approximately $483,356,000. AQR Capital Management LLC grew its holdings in DexCom by 597.8% during the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company's stock valued at $205,932,000 after buying an additional 2,658,158 shares during the last quarter. Deutsche Bank AG acquired a new stake in DexCom during the second quarter worth approximately $164,035,000. Employees Provident Fund Board acquired a new stake in DexCom in the 4th quarter worth about $145,352,000. Finally, J. Stern & Co. LLP boosted its holdings in DexCom by 2,114.8% in the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company's stock valued at $106,323,000 after acquiring an additional 1,529,641 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Stock Up 1.7%

DexCom stock opened at $90.82 on Friday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The firm has a 50 day moving average price of $79.21 and a two-hundred day moving average price of $71.60. The firm has a market cap of $34.27 billion, a price-to-earnings ratio of 35.90, a PEG ratio of 1.51 and a beta of 1.41.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. DexCom's revenue was up 13.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.48 EPS. Equities analysts predict that DexCom, Inc. will post 2.64 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DXCM. Piper Sandler reaffirmed an "overweight" rating and issued a $95.00 price target (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Citigroup reiterated a "buy" rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Mizuho raised their price objective on DexCom from $90.00 to $95.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. JPMorgan Chase & Co. increased their target price on DexCom from $65.00 to $82.00 and gave the company a "neutral" rating in a report on Friday, July 31st. Finally, Benchmark upped their target price on DexCom from $77.00 to $82.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and an average target price of $88.71.

Insider Buying and Selling

In other DexCom news, EVP Jon Coleman sold 4,911 shares of the firm's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the transaction, the executive vice president owned 95,450 shares of the company's stock, valued at approximately $7,075,708.50. This trade represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the transaction, the insider directly owned 328,970 shares of the company's stock, valued at $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 75,600 shares of company stock worth $5,673,342 over the last ninety days. Corporate insiders own 0.28% of the company's stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source